Gilead Sciences [GILD] vs Pfizer [PFE] Detailed Stock Comparison

Gilead Sciences

NASDAQ
Loading...

Pfizer

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Gilead Sciences wins in 11 metrics, Pfizer wins in 9 metrics, with 0 ties. Gilead Sciences appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricGilead SciencesPfizerBetter
P/E Ratio (TTM)22.2112.55Pfizer
Price-to-Book Ratio7.111.53Pfizer
Debt-to-Equity Ratio127.3469.70Pfizer
PEG Ratio1.020.00Pfizer
EV/EBITDA11.497.54Pfizer
Profit Margin (TTM)21.87%16.84%Gilead Sciences
Operating Margin (TTM)39.16%28.68%Gilead Sciences
EBITDA Margin (TTM)39.16%28.68%Gilead Sciences
Return on Equity33.40%12.17%Gilead Sciences
Return on Assets (TTM)12.62%5.25%Gilead Sciences
Free Cash Flow (TTM)$10.31B$9.84BGilead Sciences
Dividend Yield3.25%5.32%Pfizer
1-Year Return30.70%-5.25%Gilead Sciences
Price-to-Sales Ratio (TTM)4.842.12Pfizer
Enterprise Value$158.54B$184.71BPfizer
EV/Revenue Ratio5.492.89Pfizer
Gross Profit Margin (TTM)78.80%74.22%Gilead Sciences
Revenue per Share (TTM)$23$11Gilead Sciences
Earnings per Share (Diluted)$5.07$1.90Gilead Sciences
Beta (Stock Volatility)0.380.46Gilead Sciences
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Gilead Sciences vs Pfizer Stock Performance Analysis

Loading Price Chart...

Gilead Sciences
Pfizer
Gilead Sciences Stock Overview | Pfizer Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Gilead Sciences1.94%-0.39%-1.91%-0.85%-1.19%20.33%
Pfizer1.05%14.75%8.41%6.95%9.64%1.77%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Gilead Sciences30.70%71.97%73.18%9.85%508.48%830.64%
Pfizer-5.25%-36.01%-22.43%-14.14%63.43%17.03%

News Based Sentiment: Gilead Sciences vs Pfizer

Gilead Sciences

News based Sentiment: MIXED

October was a largely positive month for Gilead, with strong earnings and analyst upgrades offset by potential drug pricing pressures. The company's significant investments in R&D and manufacturing signal a commitment to long-term growth, but the Biktarvy pricing issue introduces a notable risk factor, creating a mixed overall investment narrative.

View Gilead Sciences News Sentiment Analysis

Pfizer

News based Sentiment: MIXED

Pfizer had a month of both positive developments – a major acquisition and strong Q2 earnings – and concerning headwinds, including looming patent expirations and increasing debt. The Metsera deal is a significant strategic move, but the overall investment story remains complex and requires careful monitoring.

View Pfizer News Sentiment Analysis

Performance & Financial Health Analysis: Gilead Sciences vs Pfizer

MetricGILDPFE
Market Information
Market Cap i$139.74B$147.88B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i7,201,15050,010,390
90 Day Avg. Volume i6,413,22343,344,040
Last Close$112.71$27.36
52 Week Range$83.98 - $121.83$20.92 - $30.43
% from 52W High-7.49%-10.07%
All-Time High$123.37 (Jun 22, 2015)$61.71 (Dec 20, 2021)
% from All-Time High-8.64%-55.66%
Growth Metrics
Quarterly Revenue Growth0.02%0.10%
Quarterly Earnings Growth0.21%69.98%
Financial Health
Profit Margin (TTM) i0.22%0.17%
Operating Margin (TTM) i0.39%0.29%
Return on Equity (TTM) i0.33%0.12%
Debt to Equity (MRQ) i127.3469.70
Cash & Liquidity
Book Value per Share (MRQ)$15.84$15.60
Cash per Share (MRQ)$4.88$2.33
Operating Cash Flow (TTM) i$9.87B$15.19B
Levered Free Cash Flow (TTM) i$8.84B$16.02B
Dividends
Last 12-Month Dividend Yield i3.25%5.32%
Last 12-Month Dividend i$3.91$1.27

Valuation & Enterprise Metrics Analysis: Gilead Sciences vs Pfizer

MetricGILDPFE
Price Ratios
P/E Ratio (TTM) i22.2112.55
Forward P/E i15.168.14
PEG Ratio i1.020.00
Price to Sales (TTM) i4.842.12
Price to Book (MRQ) i7.111.53
Market Capitalization
Market Capitalization i$139.74B$147.88B
Enterprise Value i$158.54B$184.71B
Enterprise Value Metrics
Enterprise to Revenue i5.492.89
Enterprise to EBITDA i11.497.54
Risk & Other Metrics
Beta i0.380.46
Book Value per Share (MRQ) i$15.84$15.60

Financial Statements Comparison: Gilead Sciences vs Pfizer

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)GILDPFE
Revenue/Sales i$6.67B$14.65B
Cost of Goods Sold i$1.54B$3.78B
Gross Profit i$5.13B$10.88B
Research & Development i$1.38B$2.48B
Operating Income (EBIT) i$2.49B$3.77B
EBITDA i$3.28B$5.75B
Pre-Tax Income i$1.65B$3.04B
Income Tax i$334.00M$141.00M
Net Income (Profit) i$1.32B$2.93B

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)GILDPFE
Cash & Equivalents i$7.93B$1.43B
Total Current Assets i$16.90B$45.86B
Total Current Liabilities i$12.34B$36.45B
Long-Term Debt i$22.15B$56.82B
Total Shareholders Equity i$19.08B$90.64B
Retained Earnings i$10.93B$119.59B
Property, Plant & Equipment i$7.96BN/A

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)GILDPFE
Operating Cash Flow i$1.56B$3.91B
Capital Expenditures i$-104.00M$-564.00M
Free Cash Flow i$1.65B$1.77B
Debt Repayment i$-1.76B$-2.43B
Common Stock Repurchase i$-730.00MN/A

Short Interest & Institutional Ownership Analysis

MetricGILDPFE
Shares Short i18.25M112.93M
Short Ratio i2.972.85
Short % of Float i0.01%0.02%
Average Daily Volume (10 Day) i7,201,15050,010,390
Average Daily Volume (90 Day) i6,413,22343,344,040
Shares Outstanding i1.25B5.67B
Float Shares i1.24B5.68B
% Held by Insiders i0.00%0.00%
% Held by Institutions i0.91%0.67%

Dividend Analysis & Yield Comparison: Gilead Sciences vs Pfizer

MetricGILDPFE
Last 12-Month Dividend i$3.91$1.27
Last 12-Month Dividend Yield i3.25%5.32%
3-Year Avg Annual Dividend i$3.30$1.52
3-Year Avg Dividend Yield i0.91%1.27%
3-Year Total Dividends i$9.91$4.55
Ex-Dividend DateSep 15, 2025Jan 24, 2025